澳股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Imagion Biosystems

0.024

+0.0014.35%

成交量：74.46萬

成交額：1.79萬

市值：1,177.42萬

市盈率：-1.40

高：0.024

開：0.023

低：0.023

收：0.023

52周最高：0.055

52周最低：0.011

股本：4.91億

流通股本：1.72億

量比：0.26

換手率：0.43%

股息：- -

股息率：- -

每股收益(TTM):-0.017

每股收益(LYR):-0.046

淨資產收益率：-2804.87%

總資產收益率：-83.89%

市淨率：-3.05

市盈率(LYR):-0.52

資料載入中...

總覽公司新聞資訊公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞資訊

醫學影像公司Imagion Biosystems向FDA提交Magsense® Her2靶向顯影劑二期試驗新藥臨牀試驗申請

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/IBX.AU"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"IBX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IBX.AU\",,,,,undefined,":{"symbol":"IBX.AU","market":"AU","secType":"STK","nameCN":"Imagion Biosystems","latestPrice":0.024,"timestamp":1770613920000,"preClose":0.023,"halted":0,"volume":744626,"delay":0,"changeRate":0.04347826086956526,"nameEN":"Imagion Biosystems","floatShares":172453894,"shares":490590239,"eps":-0.017095,"marketStatus":"未開盤","change":0.001,"latestTime":"02-09 16:12:00 AEDT","open":0.023,"high":0.024,"low":0.023,"amount":17870,"amplitude":0.043478,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.017095,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":0,"beginTime":1770678000000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.023,"openAndCloseTimeList":[[1770591600000,1770613200000]],"volumeRatio":0.262402767064958,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IBX.AU\",,,,,undefined,":{"symbol":"IBX.AU","floatShares":172453894,"roa":"-83.89%","roe":"-2804.87%","lyrEps":-0.045985,"volumeRatio":0.262402767064958,"shares":490590239,"dividePrice":0,"high":0.024,"amplitude":0.043478,"preClose":0.023,"low":0.023,"week52Low":0.011,"pbRate":"-3.05","psRate":"11.15","week52High":0.055,"institutionHeld":0,"latestPrice":0.024,"eps":-0.017095,"divideRate":0,"volume":744626,"delay":0,"ttmEps":-0.017095,"open":0.023,"prevYearClose":0.025,"prevWeekClose":0.023,"prevMonthClose":0.024,"prevQuarterClose":0.025,"fiveDayClose":0.025,"twentyDayClose":0.029,"sixtyDayClose":0.023,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBX.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2023-11-16","symbol":"IBX.AU","defaultRemindTime":1700089200000,"type":"split","dateTimestamp":1700053200000,"forFactor":40,"toFactor":1,"ratio":40}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBX.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBX.AU\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1161971983","title":"醫學影像公司Imagion Biosystems向FDA提交Magsense® Her2靶向顯影劑二期試驗新藥臨牀試驗申請","url":"https://stock-news.laohu8.com/highlight/detail?id=1161971983","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161971983?lang=zh_tw&edition=fundamental","pubTime":"2026-02-04 00:30","pubTimestamp":1770136219,"startTime":"0","endTime":"0","summary":"医学影像技术企业Imagion Biosystems（ASX: IBX）已正式向美国食品药品监督管理局（FDA）提交新药临床试验申请（IND），计划开展其旗舰产品Magsense® Her2靶向显影剂的二期临床试验。该显影剂采用创新纳米技术，旨在通过高精度磁共振成像实现对HER2阳性肿瘤的早期识别与定位，为乳腺癌等癌症的精准诊疗提供新方案。此次IND获批后将启动多中心临床研究，进一步验证该显影剂的安全性与成像效能，有望填补现有HER2检测技术的可视化诊断空白。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBX.AU","BK7007"],"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":1,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/IBX.AU\",params:#limit:6,delay:true,,,undefined,":[]}}